Effect of Nebulized and Intravenous Hypertonic Saline 3% on the Management of Patients With Acute Respiratory Distress Syndrome

Launched by TANTA UNIVERSITY · Jan 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how two different ways of giving a treatment called hypertonic saline (a salt solution) can help patients with a serious lung condition known as Acute Respiratory Distress Syndrome (ARDS). Specifically, the researchers want to find out if giving hypertonic saline through a nebulizer (a device that turns liquid medicine into a mist) is more effective than giving it through an intravenous (IV) injection. This study is currently looking for participants between the ages of 21 and 60 who have mild to moderate ARDS.

If you or a family member are considering participation, you would need to meet certain criteria, such as having a specific level of oxygen in your blood. However, some people may not be eligible, including those with certain cancers, advanced kidney or heart problems, or high sodium levels in their blood. If you join the trial, you can expect to receive either treatment and be monitored closely by the medical team to see how well it works for you. This study aims to improve the care and outcomes for patients suffering from ARDS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age from 21 to 60 years old.
• • Both sexes.
• • Patients with mild and moderate ARDS whose PaO2/FiO2 ratio ≥ 150 according to the Berlin definition of Acute Respiratory Distress Syndrome.
• Exclusion Criteria:
• • Refusal to participate in the study.
• • Malignancy.
• • Patients on chemotherapy.
• • Decompensated renal, hepatic and cardiac disease.
• • Patients with hypernatremia whose serum Na above 155 mEq/L.
• • Patients with ARDS whose PaO2/FiO2 ratio \> 150.